ライフサイエンスコーパス: maculopathy

1 istent uveitis, persistent hyphema, hypotony maculopathy).

2 users or severe retinal toxicity (bull's eye maculopathy).

3 1.0/1.0 for severe DR, 0.79/1.0 for diabetic maculopathy).

4 ip between PPS exposure and diagnosis of any maculopathy.

5 ndus photographs for retinal hemorrhages and maculopathy.

6 xhibit features resembling pathologic myopic maculopathy.

7 ith or without maculopathy or mild NPDR with maculopathy.

8 G), all conferring a reduced risk for toxic maculopathy.

9 AMD-associated variants on the risk of toxic maculopathy.

10 stitution with evidence of tamoxifen-induced maculopathy.

11 r evidence for any other cause of bull's eye maculopathy.

12 e, or until patients' first diagnosis with a maculopathy.

13 tion of the pathologic findings of optic pit maculopathy.

14 e users, including those at highest risk for maculopathy.

15 sease and describe 3 stages of a CRF-related maculopathy.

16 bleb revision to correct persistent hypotony maculopathy.

17 of eye care visits and diagnostic tests for maculopathy.

18 ar diseases, except those caused by diabetic maculopathy.

19 sence of coexisting paracentral acute middle maculopathy.

20 roviders and diagnostic testing to check for maculopathy.

21 We describe 3 stages of a unique CRF-related maculopathy.

22 R, majority had NPDR (93.4%), while 5.3% had maculopathy.

23 assic disease; and clearly distinct from PPS maculopathy.

24 dence of concurrent paracentral acute middle maculopathy.

25 g420Ser mutation presented with a bull's eye maculopathy.

26 accessible, and sensitive to the severity of maculopathy.

27 underwent grid photocoagulation for diabetic maculopathy.

28 No eye had associated maculopathy.

29 as glaucoma, retinal detachment, and myopic maculopathy.

30 ification and Grading System for Age-Related Maculopathy.

31 suppress radiation optic neuropathy (RON) or maculopathy.

32 ions in RDH5 and suffered from FAP with mild maculopathy.

33 vidence of disease clearly distinct from PPS maculopathy.

34 field in early stages of hydroxychloroquine maculopathy.

35 ermany) in persons with and without diabetic maculopathy.

36 rix and previously implicated in early-onset maculopathy.

37 control subjects and patients with diabetic maculopathy.

38 ared with those in aged control eyes without maculopathy.

39 despread retinal degeneration with prominent maculopathy.

40 the management of radiation retinopathy and maculopathy.

41 oven treatments for radiation retinopathy or maculopathy.

42 expansion is an early change in age-related maculopathy.

43 , and even heterozygous carriers can exhibit maculopathy.

44 dystrophy and one with bilateral progressive maculopathy.

45 ative AMD, hereditary maculopathy, and toxic maculopathy.

46 e were categorized incorrectly as having PPS maculopathy.

47 y dystrophy, or an aggregate variable of any maculopathy.

48 ed with a new presentation of optic disc pit maculopathy.

49 set were correctly categorized as having PPS maculopathy.

50 eview of previously untreated optic disc pit maculopathy.

51 ve the timing and the management of diabetic maculopathy.

52 limit vision loss associated with radiation maculopathy.

53 een PPS exposure and subsequent diagnosis of maculopathy.

54 l-domain (SD) OCT documentation of radiation maculopathy.

55 culopathies such as paracentral acute middle maculopathy.

56 ociation between binary PPS exposure and any maculopathy.

57 tional Classification System for Age-Related Maculopathy.

58 macular fluid resolution, and recurrence of maculopathy.

59 r fluid and long-term avoidance of recurrent maculopathy.

60 l atrophy, which resembles pathologic myopic maculopathy.

61 should be performed to rule out preexisting maculopathy.

62 important implications in the management of maculopathies.

63 enetic association studies of rare inherited maculopathies.

64 intraretinal fluid across various exudative maculopathies.

65 ded to regions of SSPiM in several exudative maculopathies.

66 rusen (0.8%), nonexudative AMD (0.3%), toxic maculopathy (0.1%), and hereditary dystrophy (0.04%).

67 prescription and were diagnosed later with a maculopathy (2.37%) was very similar to the percentage o

68 There were 183 individuals without any maculopathy, 200 with mild maculopathy, 325 with interme

69 een of the 64 eyes with low IOP had hypotony maculopathy (23.4%).

70 as having findings highly suggestive of PPS maculopathy; 25 patients showed some features resembling

71 Among those at high risk for maculopathy, 27.9% lacked regular eye care visits, 6.1%

72 duals without any maculopathy, 200 with mild maculopathy, 325 with intermediate disease, and 222 with

73 therapy-related complications were radiation maculopathy (43.1%) and radiation optic neuropathy (20.8

74 phototoxicity resulting from laser or solar maculopathy (5 eyes); and macular telangiectasia type 2

75 (75%); proliferative retinopathy, 24% (32%); maculopathy, 56% (65%); papillopathy, 61% (77%); catarac

76 hytherapy-related complication was radiation maculopathy (66% of patients), followed by radiation opt

77 cidence of bleb revision in patients who had maculopathy (7.6 vs. 1.9 revisions/100 person-years; for

78 s, 35% of CD and 51% of CRD had a bull's eye maculopathy; 70% of CRD showed absolute peripheral visua

79 en patients (76.5%) had a clinical radiation maculopathy; 8 patients (47.1%) had macular cysts on OCT

80 nal case series of 4 patients with optic pit maculopathy, a complete ophthalmic evaluation, with fund

81 ith acute exudative polymorphous vitelliform maculopathy (AEPVM).

82 damental insights into the unique biology of maculopathies affecting the RPE-ECM interface.

83 ctive and simple technique to treat hypotony maculopathy after glaucoma surgery.

84 of IOP and improved VA in eyes with hypotony maculopathy after previous glaucoma filtering surgery.

85 een January 2011 and July 2014 for radiation maculopathy after proton beam therapy were included.

86 atus (ELOVL2, FADS1, and FADS2), and various maculopathies (ALDH3A2 and RPE65).

87 The imaging characteristics of PPS maculopathy allow for differentiation from hereditary ma

88 tive paraneoplastic polymorphous vitelliform maculopathy, although with less distinct appearance and

89 e patient-specific hiPSCs to model and study maculopathies, an important class of blinding disorders

90 o be significantly enriched in patients with maculopathies and cone disorders (6/488) compared with e

91 l thickness is an important factor in myopic maculopathy and can be a better indicator of its severit

92 full-thickness LC defects unassociated with maculopathy and different from glaucomatous acquired pit

93 t report on the prognosis of acute traumatic maculopathy and extramacular commotio retinae.

94 wo-generation family with autosomal dominant maculopathy and identified a rare variant p.Glu1144Lys i

95 International Classification of Age-related Maculopathy and Macular Degeneration.

96 Traumatic maculopathy and massive SRH after closed-globe injury of

97 toxicity eventually leading to irreversible maculopathy and retinopathy.

98 tional Classification System for age-related maculopathy and stratified using the Rotterdam staging s

99 also referred to as paracentral acute middle maculopathy, and 5 eyes (4 patients) had type 2 SD-OCT l

100 retinal fluid, reactive exudation, radiation maculopathy, and brain metastasis.

101 nt for additional glaucoma surgery, hypotony maculopathy, and serious complications were also conside

102 and cumulative incidence of any retinopathy, maculopathy, and sight-threatening diabetic retinopathy

103 primary goal of therapy for paraproteinemic maculopathy, and this can be achieved by a systemic rout

104 isease (HFMD) and concurrent acute monocular maculopathy, and to describe multimodal imaging findings

105 egeneration (AMD), exudative AMD, hereditary maculopathy, and toxic maculopathy.

106 ure; short stature; hearing loss; pigmentary maculopathy; and renal tubular dysfunction.

107 These data indicate signs of age-related maculopathy are common in people 75 years of age or olde

108 traction mechanisms causing myopic traction maculopathy are diverse.

109 Radiation retinopathy and maculopathy are predictable complications resulting from

110 ng in ARMA, a study of aging and age-related maculopathy (ARM) ancillary to the Health, Aging, and Bo

111 lassified into two groups: early age-related maculopathy (ARM) and neovascular AMD.

112 (MMP2) genes are associated with age-related maculopathy (ARM) in older women.

113 Age-related maculopathy (ARM) is a leading cause of visual impairmen

114 Age-related maculopathy (ARM) is an important cause of visual impair

115 Macular drusen are hallmarks of age-related maculopathy (ARM), but these focal extracellular lesions

116 Age-related maculopathy (ARM), or age-related macular degeneration,

117 tary factors have been linked to age-related maculopathy (ARM), the early form of age-related macular

118 tudies of families affected with age-related maculopathy (ARM), we previously identified a significan

119 in aging and lesion formation in age-related maculopathy (ARM).

120 s test and the focal cone ERG in age-related maculopathy (ARM).

121 esions associated with aging and age-related maculopathy (ARM).

122 ior uveitis with acute hypotony and hypotony maculopathy as their first uveitic episode.

123 y, chronic central serous chorioretinopathy, maculopathy associated with hydroxychloroquine, and heal

124 d population, many patients at high risk for maculopathy associated with the use of chloroquine or hy

125 out generalized photoreceptor dysfunction to maculopathy associated with very severe rod-cone dysfunc

126 l case series of patients presented by solar maculopathy at Ophthalmology department, Sohag Universit

127 Seven patients had bilateral bull's-eye maculopathy at presentation.

128 Since 2006, 53 patients with hypotony maculopathy attributable to overfiltration following gla

129 ) were performed in patients with bull's-eye maculopathy (BEM) to identify phenotypic markers that ca

130 patients showed some features resembling PPS maculopathy but not classic disease; and 1091 patients s

131 per-reflective spot resembling that in ghost maculopathy, but corresponding SD OCT images were consis

132 PS maculopathy; some features resembling PPS maculopathy, but not classic disease; and clearly distin

133 libercept is effective in treating radiation maculopathy, but requires an ongoing treatment approach.

134 nt vitreoretinal surgery for myopic traction maculopathy by a single surgeon at a tertiary referral c

135 99.6% specificity for identification of PPS maculopathy by masked review of fundus imaging in this d

136 The peculiar features of cavitary optic disc maculopathy can be explained only by considering the pre

137 BCVA reduction in eyes with dry-type myopic maculopathy can be related to a thinner macular choroida

138 Paraproteinemic maculopathy can be unilateral.

139 Acute exudative polymorphous vitelliform maculopathy can present with a more variable natural cou

140 Dengue maculopathy can present with a unique constellation of f

141 pathy, traumatic choroidal rupture, diabetic maculopathy, central serous retinopathy, and macular dru

142 Among individuals with no or minimal maculopathy, CFH variants were associated with more than

143 cavitation, are associated with an enigmatic maculopathy characterized by schisis-like thickening and

144 ients showed visually compromising radiation maculopathy confirmed by a decline in best-corrected vis

145 hearing loss was referred for an unspecified maculopathy detected during screening evaluation for dia

146 Accelerated AMD-like maculopathy develops in patients with retinal iron overl

147 Cavitary optic disc maculopathy develops when fluctuating pressure gradients

148 by altered choroidal hemodynamics, including maculopathies, diabetic retinopathy, and glaucoma.

149 inflammatory, ischemic foveolitis, and outer maculopathy (DIII-FOM) and assess the serial changes in

150 ers, and 34.5% had no diagnostic testing for maculopathy during the 5-year period.

151 s had progressive visual loss from a type of maculopathy during the last 40 years of his life.

152 The types of maculopathies encountered were: a full-thickness macular

153 sociated with retinoschisis, myopic traction maculopathy, epiretinal membrane, vitreoretinal traction

154 D can occur in cases of high myopic traction maculopathy, especially in those without obvious vitreom

155 f 22 consecutive patients with cavitary disc maculopathy evaluated by a single surgeon between 1991 a

156 hy allow for differentiation from hereditary maculopathies even in the absence of known exposure to t

157 3/60) due to macular diseases, with diabetic maculopathy excluded.

158 d markedly reduced visual acuity, bull's eye maculopathy, foveal hyperpigmentation, peripapillary atr

159 ed by using a modified Wisconsin Age-Related Maculopathy Grading Scale (a 6-level scale: 10, no AMD;

160 AMD lesions using the Wisconsin Age-Related Maculopathy grading scheme.

161 graded according to the Clinical Age-Related Maculopathy Grading System (CARMS) as grade 1 (no AMD),

162 were graded using the Wisconsin Age-Related Maculopathy Grading System (WARMGS).

163 raphs according to the Wisconsin Age-Related Maculopathy Grading System and Airlie House classificati

164 assessed by use of the Wisconsin Age-Related Maculopathy Grading System on retinal photographs and ad

165 The Wisconsin Age-Related Maculopathy Grading System was used to grade features of

166 was assessed using the Wisconsin Age-related Maculopathy Grading System, and severity was defined usi

167 g classifications (the Wisconsin age-related maculopathy grading system, the international classifica

168 phy using the modified Wisconsin Age-Related Maculopathy Grading System.

169 photographs using the Wisconsin Age-Related Maculopathy Grading System.

170 phy using the modified Wisconsin Age-Related Maculopathy Grading System.

171 raphs according to the Wisconsin Age-Related Maculopathy Grading System.

172 raphs according to the Wisconsin Age-Related Maculopathy Grading System.

173 a modification of the Wisconsin Age-Related Maculopathy Grading System.

174 raphs according to the Wisconsin Age-Related Maculopathy grading system.

175 aded for AMD using the Wisconsin Age-related Maculopathy Grading System.

176 raded using a modified Wisconsin Age-Related Maculopathy Grading System.

177 Solar maculopathy has a good prognosis yet shows no improvemen

178 usen, nonexudative AMD, exudative AMD, toxic maculopathy, hereditary dystrophy, or an aggregate varia

179 nt mottling in 27 patients (63%) and lacunar maculopathy in 3 (6.9%).

180 lated macular degeneration (AMD), a frequent maculopathy in individuals over 55 years of age, and (2)

181 We ascertained the clinical course of maculopathy in paraproteinemia and investigated the effe

182 The most common diagnoses of maculopathy in patients with IC were exudative AMD (1.5%

183 All 10 patients with PPS maculopathy in this dataset were correctly categorized a

184 al vasculopathy and paracentral acute middle maculopathy include eye compression injury causing globa

185 Eyes with various forms of exudative maculopathy including diabetic retinopathy (DR), retinal

186 ce may be used to classify paracentral acute maculopathy into distinct subtypes.

187 The pathophysiology of dengue maculopathy involves both ischemic and inflammatory comp

188 Optic disc pit with associated maculopathy is a known entity.

189 asia is a phenocopy of grade 1 NCMD, torpedo maculopathy is a phenocopy of grade 2 NCMD, and in this

190 Recessive Stargardt maculopathy is another central blinding disease caused b

191 Tamoxifen maculopathy is characterized by cavitation in the centra

192 people in the United States with age-related maculopathy is increasing in recent years because of inc

193 ent of genetic factors contributing to toxic maculopathy is largely unclear.

194 patients with disc anomalies associated with maculopathy is mandatory.

195 Myopia-related maculopathy is one of the leading causes of blindness in

196 Ghost maculopathy is the phenomenon of an imaging artifact app

197 orrhage [k; 95 % CI = 0.60 (0.41-0.78)], and maculopathy [k; 95 % CI = 0.52 (0.43-0.60)].

198 = 0.68 (0.52-0.84)], moderate agreement for maculopathy [k; 95 % CI = 0.59 (0.50-0.67)].

199 from 5 centers with paracentral acute middle maculopathy lesions and previously unreported retinal va

200 Paracentral acute middle maculopathy lesions correspond to preservation of perfus

201 T analysis of these paracentral acute middle maculopathy lesions demonstrated subsequent thinning of

202 Paracentral acute middle maculopathy lesions may develop in a wide spectrum of re

203 alysis excluded most of the previously known maculopathy loci.

204 Many patients with optic disc pit maculopathy maintain good long-term visual acuity and ma

205 Paracentral acute middle maculopathy may be best evaluated with the use of en fac

206 Bilateral, profound hypotony maculopathy may present acutely in idiopathic acute ante

207 Paracentral acute middle maculopathy may represent a novel variant of AMN that af

208 macular edema, clinically evident radiation maculopathy, moderate vision loss, and poor visual acuit

209 Ten eyes had stage 3 CRF-related maculopathy, more common in older individuals with more

210 cal pathogenic mechanism responsible for the maculopathy, namely, dynamic fluctuations in the gradien

211 rum of acute oxygenation-based hypoperfusion maculopathy (OHM) is consistent with that predictable fr

212 Eight patients (67%) had obvious maculopathy on fundus examination.

213 Optic pit maculopathy (OPM) is an uncommon cause of vision loss wi

214 ve complications include characterization of maculopathy or corneal wound integrity, assessment of IO

215 or worse in 3 eyes, of which all had myopic maculopathy or deep amblyopia.

216 , or proliferative DR (PDR), with or without maculopathy or mild NPDR with maculopathy.

217 STDR; defined as proliferative DR, referable maculopathy, or both) was 21.0% (95% CI, 16.7%-25.3%).

218 dence (0%) of radiation-induced retinopathy, maculopathy, or optic neuropathy.

219 a Stargardt-like flecked fundus, bull's eye maculopathy, or pattern dystrophy.

220 e age-related macular degeneration, diabetic maculopathy, or retinal vein occlusion.

221 /100 person-years; for maculopathy versus no maculopathy P = 0.008).

222 (P = 0.045) and clinically evident radiation maculopathy (P = 0.040) in the bevacizumab group compare

223 13), and 0.050 (-0.40, 0.70) in Junius Kuhnt maculopathy (p = 0.344).

224 lusion illustrating paracentral acute middle maculopathy (PAMM) in a perivenular fern-like pattern wi

225 (SD-OCT) finding of paracentral acute middle maculopathy (PAMM) that can be associated with acute mac

226 tion complications, which included radiation maculopathy, papillopathy, retinal detachment, and rubeo

227 Sequencing of 192 maculopathy patients revealed additional rare variants,

228 Persistent placoid maculopathy (PPM) is a rare clinical entity with feature

229 inopathy (human graded as either ungradable, maculopathy, preproliferative, or proliferative), 99.6%

230 Surgical repair for hypotony maculopathy provided a significant improvement in VA at

231 All 6 eyes demonstrated a pigmentary maculopathy ranging from mild to pronounced.

232 mm(-1) in eyes with paracentral acute middle maculopathy (reduction -19.4%, P = .04).

233 mm(-1) in eyes with paracentral acute middle maculopathy (reduction -6.0%, P = .08).

234 Paracentral acute middle maculopathy refers to characteristic hyper-reflective sp

235 Permanent cure of the maculopathy requires either elimination of the translami

236 The maculopathy resolved partially or completely in 17 patie

237 Patients with age-related maculopathy sensitivity 2 (ARMS2) risk alleles derived m

238 g of CERKL as a first candidate: early-onset maculopathy, severe generalized retinal dysfunction, per

239 Maculopathy showed residual foveal islands or extensive

240 images as follows: highly suggestive of PPS maculopathy; some features resembling PPS maculopathy, b

241 gories using a modified Clinical Age-Related Maculopathy Staging (CARMS) system.

242 f AMD as defined by the Clinical Age-Related Maculopathy Staging system based on color fundus photogr

243 s made according to the Clinical Age-Related Maculopathy Staging System.

244 opathy Study (2001-2002) and the Age-Related Maculopathy Statin Study (2004-2006).

245 s: the Cardiovascular Health and Age-Related Maculopathy Study (2001-2002) and the Age-Related Maculo

246 tcomeMeasures: Mean Early Treatment Diabetic Maculopathy Study (ETDRS) BCVA change from baseline.

247 (346 sib pairs) from the Family Age Related Maculopathy Study (FARMS).

248 evious GWS on AMD (FARMS [Family Age-Related Maculopathy Study]sample of 34 extended families) lookin

249 idiopathic condition resembling other acute maculopathies such as paracentral acute middle maculopat

250 sterile vitreitis, endophthalmitis, hypotony maculopathy, suprachoroidal hemorrhage, retinal detachme

251 r 2 alleles associated with AMD, age-related maculopathy susceptibility 2 (ARMS2) and complement fact

252 body mass index, smoking status, age-related maculopathy susceptibility 2 (ARMS2) and complement fact

253 s of the A69S risk allele in the age-related maculopathy susceptibility 2 (ARMS2) gene (P < .001).

254 the complement factor H (CFH) or age-related maculopathy susceptibility 2 (ARMS2) genes, genotyped or

255 he complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genes.

256 ent Factor H (CFH) RS1061170 and Age Related Maculopathy Susceptibility 2 (ARMS2) RS3793917 were inde

257 ent factor H (CFH)-rs1061170 and age-related maculopathy susceptibility 2 (ARMS2)-rs10490924 polymorp

258 complement factor H (rs1061170), age-related maculopathy susceptibility 2 (rs10490924), complement co

259 amino acid substitutions in the age-related maculopathy susceptibility 2 gene linked to AMD, Ala(69)

260 es in a joint effect analysis of Age-Related Maculopathy Susceptibility 2 rs10490924 and Complement F

261 established AMD risk loci ARMS2 (age-related maculopathy susceptibility 2)-HTRA1 (HtrA serine peptida

262 AMD genes [complement factor H, age-related maculopathy susceptibility 2/high-temperature requiremen

263 enes [complement factor H (CFH), age-related maculopathy susceptibility 2/high-temperature requiremen

264 ement factor H (CFH) and A69S in age-related maculopathy susceptibility locus 2 (ARMS2).

265 andheld laser devices can cause a variety of maculopathies that can reduce central vision permanently

266 ly variable with clear impact on the risk of maculopathy, the dose to 20% of the optic disc had the l

267 quine users and those at high risk for toxic maculopathy, the proportions with regular eye care visit

268 e "ghost image" in this phenomenon of "ghost maculopathy." The ghost image was present consistently o

269 In patients with diabetic maculopathy there was no significant difference between

270 antly reduce susceptibility to develop toxic maculopathy under CQ treatment.

271 that now can be expanded to include torpedo maculopathy, vascular changes, and hemorrhagic retinopat

272 (7.6 vs. 1.9 revisions/100 person-years; for maculopathy versus no maculopathy P = 0.008).

273 ntravitreal ranibizumab therapy for diabetic maculopathy was 0.9981 QALY, equating to an 11.6% improv

274 ively; that for clinically evident radiation maculopathy was 16% versus 31% (P = 0.001), respectively

275 Mean duration of hypotony maculopathy was 4.98 +/- 8.93 months.

276 Hypotony maculopathy was characterized by the presence of a decre

277 The incidence of radiation maculopathy was comparable (19% vs. 18% at 5 years), whe

278 minant splicing variant with late-onset mild maculopathy was established.

279 Diabetic maculopathy was found in 14.5% (59/407) of all participa

280 notypes including exudative and nonexudative maculopathy was observed, with onset in the late fifth d

281 Maculopathy was unilateral in 9 cases and occurred at a

282 ch for "diabetic macular edema" or "diabetic maculopathy" was performed using the PubMed, Cochrane Li

283 sen and other lesions typical of age-related maculopathy were determined by grading stereoscopic colo

284 of 16 patients with paracentral acute middle maculopathy were evaluated.

285 62 patients with various forms of exudative maculopathy were evaluated; 60 eyes with DR, 9 eyes with

286 All eyes with ghost maculopathy were found to be pseudophakic with a posteri

287 Those at high risk for maculopathy were identified.

288 Decreased visual acuity and early-onset maculopathy were present in all patients.

289 ted volunteers and 21 patients with diabetic maculopathy were recruited.

290 rom 8 patients with paracentral acute middle maculopathy were reviewed and analyzed.

291 retinal pathologies, retinal hemorrhage, and maculopathy were substantial both for the ophthalmologis

292 otherwise known as paracentral acute middle maculopathy, were observed in all patients at baseline p

293 itions, such as poppers retinopathy or solar maculopathy, which may have similar findings on OCT imag

294 Medical records of 33 patients with hypotony maculopathy who underwent primary bleb revision between

295 sed study, 20 eyes of 10 patients presenting maculopathies with various degrees of impairment of the

296 has the potential to provide patients having maculopathy with a new tool to monitor their vision at h

297 The mildest disease was a subtle maculopathy with relatively limited peripheral retinal d

298 gment epithelium and cystoid or schisis-like maculopathy with typical functional findings remain clas

299 rfamilial variability, ranging from isolated maculopathy without generalized photoreceptor dysfunctio

300 detachment in patients with myopic traction maculopathy without posterior vitreous detachment.